Free Trial

TScan Therapeutics 11/12/2024 Earnings Report

TScan Therapeutics logo
$1.42 +0.08 (+5.56%)
As of 12:44 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TScan Therapeutics EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.28
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

TScan Therapeutics Revenue Results

Actual Revenue
$1.05 million
Expected Revenue
$2.86 million
Beat/Miss
Missed by -$1.81 million
YoY Revenue Growth
N/A

TScan Therapeutics Announcement Details

Quarter
Time
Before Market Opens

Conference Call Resources

Remove Ads

TScan Therapeutics Earnings Headlines

TScan Therapeutics appoints Camiolo as SVP, Market Access
[OPEN NOW] New rules to trade options with.
Here’s an update that could make your entire year. But first, a question. Could you get better wins if you applied a new set of rules to your trade? For example, when you meet your criteria to take a trade, could you improve your results by taking the same trade differently? From the audit I just did, it turns out the answer is a resounding YES! I applied a new set of rules to 100 live published trades from 2024. These 100 trades already got a whopping 69% win rate – taking a $10k model account risking 10% per trade to $63,304. But what happened when we applied these new rules? We got an 85.1% win rate and sent the same $10k account risking 10% per trade to over $200k!
TScan Therapeutics assumed with an Overweight at Morgan Stanley
See More TScan Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TScan Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TScan Therapeutics and other key companies, straight to your email.

About TScan Therapeutics

TScan Therapeutics (NASDAQ:TCRX), a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

View TScan Therapeutics Profile

More Earnings Resources from MarketBeat